{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T06:20:44Z","timestamp":1770963644424,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Uncomplicated urinary tract infections (uUTIs\/acute cystitis) are among the most common infections in women worldwide. There are differences in uUTI treatment guidelines between countries and understanding the needs of physicians in diverse healthcare systems is important for developing new treatments. We performed a survey of physicians in the United States (US) and Germany to understand their perceptions of, and management approaches to uUTI.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a cross-sectional online survey of physicians in the US and Germany who were actively treating patients with uUTI (\u2265\u200910 patients\/month). Physicians were recruited via a specialist panel and the survey was piloted with 2 physicians (1 US, 1 Germany) prior to study commencement. Data were analyzed with descriptive statistics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 300 physicians were surveyed (<jats:italic>n<\/jats:italic>\u2009=\u2009200 US, <jats:italic>n<\/jats:italic>\u2009=\u2009100 Germany). Across countries and specialties, physicians estimated 16\u201343% of patients did not receive complete relief from initial therapy and 33\u201337% had recurrent infections. Urine culture and susceptibility testing was more common in the US and among urologists. The most commonly selected first-line therapy was trimethoprim-sulfamethoxazole in the US (76%) and fosfomycin in Germany (61%). Ciprofloxacin was the most selected following multiple treatment failures (51% US, 45% Germany). Overall, 35% of US and 45% of German physicians agreed with the statement \u201cI feel there is a good selection of treatment options\u201d and\u2009\u2265\u200950% felt that current treatments provided good symptom relief. More than 90% of physicians included symptom relief amongst their top 3 treatment goals. The overall impact of symptoms on patients\u2019 lives was rated \u201ca great deal\u201d by 51% of US and 38% of German physicians, increasing with each treatment failure. Most physicians (&gt;\u200980%) agreed that antimicrobial resistance (AMR) is serious, but fewer (56% US, 46% Germany) had a high level of confidence in their knowledge of AMR.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Treatment goals for uUTI were similar in the US and Germany, although with nuances to disease management approaches. Physicians recognized that treatment failures have a significant impact on patients\u2019 lives and that AMR is a serious problem, though many did not have confidence in their own knowledge of AMR.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-023-08207-x","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T13:03:43Z","timestamp":1683119023000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Unmet needs in uncomplicated urinary tract infection in the United States and Germany: a physician survey"],"prefix":"10.1186","volume":"23","author":[{"given":"Megan","family":"O\u2019Brien","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alen","family":"Marijam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanny S.","family":"Mitrani-Gold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Terry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gavin","family":"Taylor-Stokes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish V.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,3]]},"reference":[{"key":"8207_CR1","doi-asserted-by":"publisher","first-page":"175628721983217","DOI":"10.1177\/1756287219832172","volume":"11","author":"M Medina","year":"2019","unstructured":"Medina M, Castillo-Pino E. An introduction to the epidemiology and burden of urinary tract infections. Ther Adv Urol. 2019;11:1756287219832172.","journal-title":"Ther Adv Urol"},{"issue":"5","key":"8207_CR2","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1093\/cid\/ciq257","volume":"52","author":"K Gupta","year":"2011","unstructured":"Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103\u201320.","journal-title":"Clin Infect Dis"},{"key":"8207_CR3","unstructured":"World Health Organization. Ten threats to global health in 2019: World Health Organization; 2019 [Updated 18 February 2022]. Available from: https:\/\/www.who.int\/news-room\/spotlight\/ten-threats-to-global-health-in-2019."},{"issue":"1","key":"8207_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/fampra\/cmh720","volume":"22","author":"E Hummers-Pradier","year":"2005","unstructured":"Hummers-Pradier E, Ohse AM, Koch M, Heizmann WR, Kochen MM. Management of urinary tract infections in female general practice patients. Fam Pract. 2005;22(1):71\u20137.","journal-title":"Fam Pract"},{"issue":"5","key":"8207_CR5","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.eururo.2020.06.032","volume":"78","author":"KG Naber","year":"2020","unstructured":"Naber KG, Bonkat G, Wagenlehner FME. The EAU and AUA\/CUA\/SUFU Guidelines on recurrent urinary tract infections: what is the difference? Eur Urol. 2020;78(5):645\u20136.","journal-title":"Eur Urol"},{"key":"8207_CR6","unstructured":"Bonkat G, Bartoletti R, Bruyere F, Cai T, Geerlings S, Koves B, et al. European Association of Urology guidelines: Urological infections 2021 [Available from: https:\/\/uroweb.org\/guidelines\/urological-infections]."},{"issue":"12","key":"8207_CR7","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nrurol.2010.190","volume":"7","author":"B Foxman","year":"2010","unstructured":"Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol. 2010;7(12):653\u201360.","journal-title":"Nat Rev Urol"},{"issue":"665","key":"8207_CR8","doi-asserted-by":"publisher","first-page":"e830","DOI":"10.3399\/bjgp17X693641","volume":"67","author":"CC Butler","year":"2017","unstructured":"Butler CC, Francis N, Thomas-Jones E, Llor C, Bongrad E, Moore M, et al. Variations in presentation, management, and patient outcomes of urinary tract infection: a prospective four-country primary care observational cohort study. Br J Gen Pract. 2017;67(665):e830\u201341.","journal-title":"Br J Gen Pract"},{"issue":"2","key":"8207_CR9","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1742-1241.2006.01277.x","volume":"61","author":"FW Platt","year":"2007","unstructured":"Platt FW, Keating KN. Differences in physician and patient perceptions of uncomplicated UTI symptom severity: understanding the communication gap. Int J Clin Pract. 2007;61(2):303\u20138.","journal-title":"Int J Clin Pract"},{"issue":"694","key":"8207_CR10","doi-asserted-by":"publisher","first-page":"e330","DOI":"10.3399\/bjgp20X708173","volume":"70","author":"DM Lecky","year":"2020","unstructured":"Lecky DM, Howdle J, Butler CC, McNulty CAM. Optimising management of UTIs in primary care: a qualitative study of patient and GP perspectives to inform the development of an evidence-based, shared decision-making resource. Br J Gen Pract. 2020;70(694):e330\u20138.","journal-title":"Br J Gen Pract"},{"issue":"2","key":"8207_CR11","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1177\/1715163521989756","volume":"154","author":"AJ Chan","year":"2021","unstructured":"Chan AJ, O\u2019Donnell D, Kaasa B, Mathers A, Papaioannou A, Brazil K, et al. Barriers and facilitators of implementing an antimicrobial stewardship intervention for urinary tract infection in a long-term care facility. Can Pharm J (Ott). 2021;154(2):100\u20139.","journal-title":"Can Pharm J (Ott)"},{"issue":"8","key":"8207_CR12","doi-asserted-by":"publisher","first-page":"e2225730","DOI":"10.1001\/jamanetworkopen.2022.25730","volume":"5","author":"JY Kikuchi","year":"2022","unstructured":"Kikuchi JY, Banaag A, Koehlmoos TP. Antibiotic prescribing patterns and guideline concordance for uncomplicated urinary tract infections among adult women in the US military health system. JAMA Netw Open. 2022;5(8):e2225730.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"8207_CR13","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1097\/JU.0000000000000296","volume":"202","author":"J Anger","year":"2019","unstructured":"Anger J, Lee U, Lenore Ackerman A, Chou R, Chughtai B, Quentin Clemens J, et al. Recurrent uncomplicated urinary tract infections in women: AUA\/CUA\/SUFU guideline. J Urol. 2019;202(2):282\u20139.","journal-title":"J Urol"},{"issue":"1","key":"8207_CR14","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3109\/02813432.2012.751695","volume":"31","author":"I Bjorkman","year":"2013","unstructured":"Bjorkman I, Berg J, Viberg N, Stalsby LC. Awareness of antibiotic resistance and antibiotic prescribing in UTI treatment: a qualitative study among primary care physicians in Sweden. Scand J Prim Health Care. 2013;31(1):50\u20135.","journal-title":"Scand J Prim Health Care"},{"issue":"3","key":"8207_CR15","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1159\/000487645","volume":"100","author":"J Kranz","year":"2018","unstructured":"Kranz J, Schmidt S, Lebert C, Schneidewind L, Mandraka F, Kunze M, et al. The 2017 update of the German clinical guideline on epidemiology, diagnostics, therapy, prevention, and management of uncomplicated urinary tract infections in adult patients. Part II: therapy and prevention. Urol Int. 2018;100(3):271\u20138.","journal-title":"Urol Int."},{"issue":"11","key":"8207_CR16","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1093\/cid\/ciab560","volume":"73","author":"KS Kaye","year":"2021","unstructured":"Kaye KS, Gupta V, Mulgirigama A, Joshi AV, Scangarella-Oman NE, Yu K, et al. Antimicrobial resistance trends in urine Escherichia coli isolates from adult and adolescent females in the United States from 2011\u20132019: Rising ESBL strains and impact on patient management. Clin Infect Dis. 2021;73(11):1992\u20139.","journal-title":"Clin Infect Dis"},{"key":"8207_CR17","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients 2018 [Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-about-increased-risk-ruptures-or-tears-aorta-blood-vessel-fluoroquinolone-antibiotics]."},{"key":"8207_CR18","unstructured":"European Medicines Agency. Fluoroquinolone and quinolone antibiotics: PRAC recommends new restrictions on use following review of disabling and potentially long-lasting side effects 2018 [Available from: https:\/\/www.ema.europa.eu\/en\/news\/fluoroquinolone-quinolone-antibiotics-prac-recommends-new-restrictions-use-following-review]."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08207-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08207-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08207-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T13:03:56Z","timestamp":1683119036000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08207-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,3]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["8207"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08207-x","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,3]]},"assertion":[{"value":"19 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Physician data was collected via Medefield, a global physician panel powered by their LiMA (Leaders in Medicine Atlas) offering. A statement of informed consent was provided during pre-screening and respondents were informed of their rights under general data protection regulation and other national, regional and local laws pertaining to privacy and data protection. This study complied with all applicable laws regarding subject privacy and all methods were performed in accordance with the relevant guidelines and regulations (e.g., Declaration of Helsinki). No direct subject contact or primary collection of individual human subject data occurred. Ethical approval of the protocol, consent forms and survey was granted by Western Institutional Review Board-Copernicus Group (WCG) Institutional Review Board (IRB) (Puyallup, WA, USA; IRB tracking number: 20203712).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare the following potential conflicts of interest: MO and LT were employees of Adelphi Real World at the time of the study and GT-S is a current employee of Adelphi Real World, which received funding from GSK to conduct this study. AM, FSM-G and AVJ are employees of and shareholders in GSK.Some of the data contained in this manuscript were previously presented at IDWeek 2021 Virtual Congress, Abstract 1435 \u201cUnmet Needs in Uncomplicated Urinary Tract Infection in the United States and Germany: A Physician Survey\u201d.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"281"}}